|drug4818||Оxygen therapy Wiki||0.71|
|drug2856||Penn Microbiome Therapy - 001 Wiki||0.71|
|drug2999||Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells Wiki||0.71|
|D004761||Enterocolitis, Pseudomembranous NIH||0.71|
|D003015||Clostridium Infections NIH||0.50|
|D003141||Communicable Diseases NIH||0.05|
There are 2 clinical trials
This is a randomized, open label, comparative, Phase II study to determine whether fecal microbiota transplant using Penn Microbiome Therapy products helps standard therapy to treat severe Clostridium difficile infection (C diff).
Description: The outcome will be satisfied when the subject is discharged from the hospital (not to hospice or palliative care) or, while the subject remains hospitalized, when the following criteria are met for 24 hours: If radiology study or studies performed, ileus/dilation/megacolon either not noted or noted as resolved Ileus/megacolon either noted as resolved by any provider documentation or not noted WBC<15,000 cells/uL Serum creatinine decreased, unchanged, or increased by ≤0.2 mg/dL over 24 hours (if not receiving continuous renal replacement therapy (CRRT) or hemodialysis (HD)) Lactate ≤2.2 mmol/L (if measured by clinical care team) No vasopressors used (including epinephrine, norepinephrine, phenylephrine, or vasopressin) Temperature <38.5 °C and ≥35.6°C < 8 bowel movements per day and < 600 mL unformed stool (if volume recorded) Meeting fewer than 3 systemic inflammatory response syndrome (SIRS) criteriaMeasure: Number of subjects with resolution of symptoms after treatment with one of the PMT suite of products. Time: 7 Days
Description: All-cause mortality at 30- and 60-days following last FMT Colectomy or diverting ileostomy within 30 days after last FMT Cumulative days of hospitalization from enrollment until 30 days after FMT Cumulative days in intensive care unit from enrollment until 30 days after last FMT Bacteremia from enrollment until 30 days after last FMT Repeat hospital admission within 60 days of discharge from index hospitalizationMeasure: Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE V5.0 Time: 180 Days
Assessment of the clinical effects of infusions of cryopreserved allogeneic multipotent mesenchymal stem cells of the placenta and umbilical cord for COVID-19 patients with acute respiratory distress syndrome.
Description: Improvement of pulmonary function. Arterial oxygen tension PaO2 (in mmHg)/fractional inspired oxygen FiO2 (expressed as a fraction, not a percentage), most conveniently the P/F ratio. The normal P/F ratio is ~ 400-500 mmHg (~55-65 kPa). P/F ratio <300mmHg - sign of Acute Respiratory Distress Syndrome (ARDS)Measure: Changes of oxygenation index PaO2/FiO2, most conveniently the P/F ratio. Time: up to 28 days
Description: Length of Hospital StayMeasure: Changes in length of hospital stay Time: up to 28 days
Description: Marker for efficacy of treatmentMeasure: Changes in mortality rate Time: up to 28 days
Description: Infection biomarker. Serum CRP levels can be used for early diagnosis of pneumonia, patients with severe pneumonia had high CRP levels.Measure: Changes of С-reactive protein (CRP, mg/L) Time: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
Description: CT assessment of pulmonary lesions and lung tissue changesMeasure: Evaluation of Pneumonia Improvement Time: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
Description: Indirect response to lung functionMeasure: Duration of respiratory symptoms (difficulty breathing, dry cough, fever, etc.) Time: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
Description: Degree of infectionMeasure: Peripheral blood count recovery time Time: At baseline, Day 1, Week 1, Week 2, Week 4, Week 8
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports